J. Ford

11.7k total citations · 2 hit papers
58 papers, 8.6k citations indexed

About

J. Ford is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, J. Ford has authored 58 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hematology, 25 papers in Oncology and 23 papers in Genetics. Recurrent topics in J. Ford's work include Bone health and treatments (15 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Hemoglobinopathies and Related Disorders (12 papers). J. Ford is often cited by papers focused on Bone health and treatments (15 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Hemoglobinopathies and Related Disorders (12 papers). J. Ford collaborates with scholars based in Switzerland, United States and United Kingdom. J. Ford's co-authors include Brian Druker, Renaud Capdeville, Charles L. Sawyers, Moshe Talpaz, Debra Resta, Hagop M. Kantarjian, Bin Peng, Nicholas Lydon, Elisabeth Buchdunger and Sayuri Ohno-Jones and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

J. Ford

57 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

2001 3.8k citations Brian Druker, Moshe Talpaz et al. New England Journal of Medicine profile →
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

2001 2.1k citations Brian Druker, Charles L. Sawyers et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Ford Switzerland	26	4.9k	3.4k	2.3k	2.2k	1.8k	58	8.6k
Josy Reiffers France	48	6.6k 1.3×	3.2k 1.0×	1.9k 0.8×	1.5k 0.7×	1.7k 0.9×	223	9.1k
Fabrizio Pane Italy	42	6.7k 1.4×	4.9k 1.5×	1.3k 0.6×	2.7k 1.3×	1.9k 1.0×	289	9.4k
Bruno Varet France	37	4.1k 0.8×	2.6k 0.8×	1.4k 0.6×	1.0k 0.5×	1.7k 0.9×	145	7.6k
Nicole Casadevall France	51	5.5k 1.1×	4.5k 1.3×	1.3k 0.6×	1.7k 0.8×	3.4k 1.9×	167	10.5k
Hagop Kantarjian United States	38	5.0k 1.0×	3.2k 1.0×	1.6k 0.7×	1.6k 0.7×	1.9k 1.1×	140	7.5k
Meir Wetzler United States	48	5.0k 1.0×	2.1k 0.6×	2.1k 0.9×	635 0.3×	3.0k 1.6×	245	8.6k
Gérald Marit France	43	5.9k 1.2×	2.2k 0.6×	3.3k 1.4×	768 0.4×	3.3k 1.8×	193	8.6k
Oliver G. Ottmann Germany	62	10.4k 2.1×	5.0k 1.5×	4.0k 1.8×	2.8k 1.3×	4.9k 2.7×	372	16.1k
Jerry A. Katzmann United States	54	5.4k 1.1×	2.6k 0.8×	2.6k 1.2×	530 0.2×	5.1k 2.8×	171	10.6k
Marilyn L. Slovak United States	46	6.9k 1.4×	2.3k 0.7×	4.0k 1.8×	543 0.3×	4.4k 2.4×	152	11.7k

Countries citing papers authored by J. Ford

Since Specialization

Citations

This map shows the geographic impact of J. Ford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Ford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Ford more than expected).

Fields of papers citing papers by J. Ford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Ford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Ford. The network helps show where J. Ford may publish in the future.

Co-authorship network of co-authors of J. Ford

This figure shows the co-authorship network connecting the top 25 collaborators of J. Ford. A scholar is included among the top collaborators of J. Ford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Ford. J. Ford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Symmons, Sophie Mulcahy, David Mockler, Pádraic Fleming, et al.. (2025). How and why do health system factors influence general dentists’ participation in publicly funded, contracted primary dental care services: A realist review. Health Policy. 153. 105248–105248.

Capelleveen, Julian C. van, John J.P. Kastelein, Aeilko H. Zwinderman, et al.. (2016). Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. Journal of clinical lipidology. 10(5). 1137–1144.e3. 33 indexed citations

Hovingh, G. Kees, John J.P. Kastelein, Sander J. H. van Deventer, et al.. (2015). Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet. 386(9992). 452–460. 176 indexed citations

Galanello, Renzo, Antonio Piga, Maria Domenica Cappellini, et al.. (2008). Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen. The Journal of Clinical Pharmacology. 48(4). 428–435. 34 indexed citations

Capdeville, Renaud, et al.. (2008). Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias. Annals of Oncology. 19(7). 1320–1326. 12 indexed citations

Cappellini, Maria Domenica, Patricia J. Giardina, John B. Porter, et al.. (2006). Long-Term Safety and Tolerability of the Once-Daily, Oral Iron Chelator Deferasirox (Exjade®, ICL670) in Patients with Transfusional Iron Overload.. Blood. 108(11). 1768–1768. 8 indexed citations

Cappellini, Maria Domenica, Mohamed Béjaoui, Leyla Ağaoğlu, et al.. (2005). Patient Satisfaction with Deferasirox (Exjade®, ICL670) an Oral Form of Chelation Therapy Versus Deferoxamine an Infused Chelation Therapy.. Blood. 106(11). 2704–2704. 12 indexed citations

Erdem, Güliz, et al.. (2005). Molecular Epidemiologic Comparison of 2 Unusual Clusters of Group A Streptococcal Necrotizing Fasciitis in Hawaii. Clinical Infectious Diseases. 40(12). 1851–1854. 10 indexed citations

Hensley, Martee L. & J. Ford. (2003). Imatinib treatment: Specific issues related to safety, fertility, and pregnancy. Seminars in Hematology. 40(2 Suppl 2). 21–25. 121 indexed citations

10.

Stentoft, Jesper, et al.. (2002). Cerebral oedema as a possible complication of treatment with imatinib. The Lancet. 359(9319). 1751–1752. 37 indexed citations

11.

Zubay, Geoffrey, Brian Druker, Moshe Talpaz, et al.. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lympoblastic leukemia with the philadelphia chromosome. 14(13). 733–738. 9 indexed citations

12.

Druker, Brian, Moshe Talpaz, Debra Resta, et al.. (2001). Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. New England Journal of Medicine. 344(14). 1031–1037. 3811 indexed citations breakdown →

13.

Druker, Brian, Charles L. Sawyers, Renaud Capdeville, et al.. (2001). Chronic Myelogenous Leukemia. Hematology. 2001(1). 87–112. 58 indexed citations

14.

Druker, Brian, Charles L. Sawyers, Hagop M. Kantarjian, et al.. (2001). Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome. New England Journal of Medicine. 344(14). 1038–1042. 2070 indexed citations breakdown →

15.

Coleman, Robert E., Stephen Houston, O.P. Purohit, et al.. (1998). A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. European Journal of Cancer. 34(6). 820–824. 33 indexed citations

16.

Knowles, T. G., S.N. Brown, P. D. Warriss, et al.. (1995). Effects on sheep of transport by road for up to 24 hours. Veterinary Record. 136(17). 431–438. 112 indexed citations

17.

Tyrrell, C., et al.. (1994). Intravenous pamidronate: infusion rate and safety.. PubMed. 5 Suppl 7. S27–9. 17 indexed citations

18.

Houston, Stephen, et al.. (1992). Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. British Journal of Cancer. 65(5). 766–768. 61 indexed citations

19.

Ford, J., Lawrence Panasci, Yves Leclerc, & R Margolese. (1987). Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer.. PubMed. 71(10). 921–5. 6 indexed citations

20.

Slevin, M L, J.A. Lowes, Richard Bell, et al.. (1981). The role of transtracheal aspiration in the diagnosis of respiratory infection in neutropenic patients with acute Leukaemia. Leukemia Research. 5(2). 165–168. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact